Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Effect of abciximab on angiographic complications during percutaneous coronary stenting in the evaluation of platelet iib/iiia inhibition in stenting trial (epistent)

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Islam, M. A.
  • Blankenship, J. C.
  • Balog, C.
  • Iliadis, E. A.
  • Lincoff, M.
  • Tcheng, J. E.
  • Califf, R. M.
  • Topol, Eric
  • EPISTENT Investigators

publication date

  • November 2002

journal

  • American Journal of Cardiology  Journal

abstract

  • In the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT), abciximab reduced ischemic complications of stent implantation at 30 days and 6 months. The responsible mechanisms remain unclear. We sought to determine if abciximab decreases ischemic complications by decreasing the incidence of angiographic complications during coronary stenting. In EPISTENT, patients were randomized to stenting with abciximab (abciximab group), stenting with placebo (placebo group), or balloon angioplasty with abciximab. Angiographic complications (including major or minor dissection, distal embolization, thrombus postprocedure, side branch or other vessel occlusion, residual stenosis >50%, transient coronary occlusion, and Thrombolysis In Myocardial Infarction final flow <3) were recorded prospectively. Creatine kinase (CK)-MB enzyme levels after intervention were measured at 6-hour intervals. We analyzed angiographic complications and CK-MB elevations in the abciximab group (n = 784) and the placebo group (n = 803). Angiographic complications were 29% less frequent in the abciximab group compared with the placebo group (17.0% vs 23.8%; p = 0.001). In patients with angiographic complications, there was a nonsignificant reduction in the incidence of CK-MB elevation >3 times normal with abciximab therapy (19.7% vs 24.5% in placebo group; p = 0.314). Abciximab (compared with placebo) significantly reduced the incidence of CK-MB elevation >3 times normal in those without any angiographic complications (6.5% vs 10.7%; p = 0.007). In summary, abciximab (compared with placebo) significantly reduced angiographic complications during coronary stenting. Abciximab also prevented CK-MB elevations in patients without angiographic complications.

subject areas

  • Angioplasty, Balloon, Coronary
  • Antibodies, Monoclonal
  • Blood Vessel Prosthesis Implantation
  • Coronary Angiography
  • Creatine Kinase
  • Creatine Kinase, MB Form
  • Double-Blind Method
  • Drug Evaluation
  • Endpoint Determination
  • Female
  • Humans
  • Immunoglobulin Fab Fragments
  • Incidence
  • Isoenzymes
  • Male
  • Myocardial Ischemia
  • North America
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Stents
  • Survival Analysis
  • Time Factors
  • Treatment Outcome
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 0002-9149

Digital Object Identifier (DOI)

  • 10.1016/s0002-9149(02)02653-x

PubMed ID

  • 12398954
scroll to property group menus

Additional Document Info

start page

  • 916

end page

  • 921

volume

  • 90

issue

  • 9

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support